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CHARGE syndrome is a well-established multiple-malformation syndrome with distinctive consensus diagnostic
criteria. Characteristic associated anomalies include ocular coloboma, choanal atresia, cranial nerve defects, dis-
tinctive external and inner ear abnormalities, hearing loss, cardiovascular malformations, urogenital anomalies,
and growth retardation. Recently, mutations of the chromodomain helicase DNA-binding protein gene CHD7 were
reported to be a major cause of CHARGE syndrome. We sequenced the CHD7 gene in 110 individuals who had
received the clinical diagnosis of CHARGE syndrome, and we detected mutations in 64 (58%). Mutations were
distributed throughout the coding exons and conserved splice sites of CHD7. Of the 64 mutations, 47 (73%)
predicted premature truncation of the protein. These included nonsense and frameshift mutations, which most
likely lead to haploinsufﬁciency. Phenotypically, the mutation-positive group was more likely to exhibit cardio-
vascular malformations (54 of 59 in the mutation-positive group vs. 30 of 42 in the mutation-negative group;
), coloboma of the eye (55 of 62 in the mutation-positive group vs. 30 of 43 in the mutation-negativePp .014
group; ), and facial asymmetry, often caused by seventh cranial nerve abnormalities (36 of 56 in thePp .022
mutation-positive group vs. 13 of 39 in the mutation-negative group; ). Mouse embryo whole-mount andPp .004
section in situ hybridization showed the expression of Chd7 in the outﬂow tract of the heart, optic vesicle, facio-
acoustic preganglion complex, brain, olfactory pit, and mandibular component of the ﬁrst branchial arch. Mi-
croarray gene-expression analysis showed a signature pattern of gene-expression differences that distinguished the
individuals with CHARGE syndrome with CHD7 mutation from the controls. We conclude that cardiovascular
malformations, coloboma, and facial asymmetry are common ﬁndings in CHARGE syndrome caused by CHD7
mutation.
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CHARGE syndrome (MIM 214800) is a distinctive syn-
drome with a complex constellation of multiple con-
genital anomalies. The incidence of CHARGE syndrome
may be as high as 1 in 8,500 births (Issekutz et al. 2005).
It is characterized by variable occurrence of coloboma,
choanal atresia or cleft lip and/or palate, cranial nerve
dysfunction, characteristic external ear malformations
with distinct temporal bone anomalies, cardiovascular
malformations, and hypogonadotropic hypogonadism
with genitourinary anomalies (Hall 1979; Hittner et al.
1979; Pagon et al. 1981; Blake et al. 1998). Inner ear
defects, including Mondini malformation and/or semi-
circular canal hypoplasia/aplasia are common and often
cause hearing loss and vestibular abnormalities in the
affected individuals (Amiel et al. 2001). Many types of
cardiovascular malformations have been reported, but
conotruncal and aortic arch malformations appear to
be more common than the others (Blake et al. 1998).
Growth delay, distinctive facial features, DiGeorge se-
quence, and tracheoesophageal ﬁstula are some of the
additional clinical features of this condition. In the 25
years since its initial characterization, the diagnostic cri-
teria for the original CHARGE acronym were revised
and standardized (Blake et al. 1998), with a further pro-
posal to update them (Verloes 2005). What was consid-
ered a prototypic “association” is now viewed as a syn-
drome in many well-deﬁned cases (Lubinsky 1994), for
which the name “Hall-Hittner syndrome” may also
apply (Graham 2001). Vissers et al. (2004) reported
mutations in the CHD7 gene, which encodes chromo-
domain helicase DNA-binding protein, in ∼60% of in-
dividuals with CHARGE syndrome. Chromatin remod-
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Figure 1 Individuals with CHARGE syndrome who haveCHD7mutations.A and a,A 17-year-old girl with retinal coloboma, characteristic
ear malformation, hearing loss, partial atrioventricular canal defect, growth retardation, and delayed puberty who has a frameshift mutation
in exon 37. B and b, An 11-year-old boy with colobomas of the iris and the macula, choanal stenosis, characteristic ear malformation, bilateral
Mondini malformation, profound hearing loss, submucous cleft palate, bilateral facial palsy, undescended testes, and pulmonary atresia with
ventricular septal defect who has a de novo frameshift mutation in exon 18. C and c, A 3-year-old boy with bilateral iris coloboma, choanal
stenosis, ear malformation, hearing loss, facial palsy, and abnormal cochlea but without cardiovascular malformation who has a nonsense
mutation in exon 13. D and d, A 12-year-old boy with coloboma involving the optic nerve, choanal atresia, characteristic ear malformation,
profound hearing loss, abnormal inner ear, patent ductus arteriosus, and genital abnormalities who has a frameshift mutation in exon 2. Note
that the individuals in panels B and D illustrate the characteristic facial appearance of CHARGE syndrome.
eling is a recognized mechanism of gene-expression
regulation, and the CHD7 gene is likely to play a sig-
niﬁcant role in embryonic development and cell-cycle
regulation (Woodage et al. 1997). The prevalence of
CHD7 mutations in a large cohort of individuals with
CHARGE syndrome and the possible correlation of spe-
ciﬁc mutations with clinical characteristics have not been
formally addressed. We report the systematic molecular
and phenotypic evaluation of 110 individuals with clin-
ical CHARGE syndrome. We identiﬁed mutations in the
CHD7 gene in 58% (64/110) of the affected individuals
and analyzed the phenotypic data of the study cohort,
using multivariate analysis conditional on the mutation
status. Our results indicate signiﬁcant phenotypic dif-
ferences between CHD7 mutation carriers and noncar-
riers and are consistent with locus heterogeneity as the
likely explanation for the group of individuals with
CHARGE syndrome whose sequence analysis of CHD7
was normal. Nucleotide sequence data reported herein
are available in the DDBJ/EMBL/GenBank databases;
for details, see the Web Resources section.
Material and Methods
Clinical Evaluation
The study sample included 110 individuals with CHARGE
syndrome who either had four major criteria for the diagnosis
of CHARGE syndrome (coloboma, choanal atresia, charac-
teristic ear abnormalities, and cranial nerve dysfunction), had
three major and three minor criteria (genital hypoplasia, de-
velopmental delay, cardiovascular malformation, growth de-
ﬁciency, orofacial cleft, tracheoesopageal ﬁstula, and charac-
teristic face), or had one or two major criteria with several
minor criteria (Blake et al. 1998) (ﬁg. 1). According to Blake
et al. (1998), individuals with all four major criteria or with
three major and three minor criteria deﬁnitely have CHARGE
syndrome, and individuals with one or two major criteria and
several minor criteria possibly have the syndrome. The children
with CHARGE syndrome and their parents were enrolled
through the CHARGE Syndrome Foundationmeetings in 1999
and 2001 and through the Baylor College of Medicine Car-
diovascular Genetics Web site. Informed consent was obtained
from participant families. Clinical histories were obtained for
all probands, as well as for any other possibly affected fam-
ily members. The medical records of the individuals with
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Figure 2 Microarray gene-expression proﬁle and the resulting
cluster analysis. Patterns of gene expression were assessed on Affy-
metrix U133Plus2.0 arrays (see “Material and Methods” section for
details). After identiﬁcation of a subset of transcripts with apparently
signiﬁcant differences in expression between the individuals with
CHARGE syndrome with CHD7 mutations and the controls, the
combined data were used to produce a hierarchical cluster analysis.
Expression values shown were standardized using the gene-speciﬁc
mean and SD of log2 expression. Note that the proﬁle of CHA230
(who had no detectable CHD7 mutation) is highly similar to those of
individuals with CHD7 mutations.
CHARGE syndrome were analyzed. The probands were as-
certained by one of the dysmorphologists (S.R.L., J.W.B.,
C.A.B., J.M.G., or S.L.H.D.). Several individuals with CHARGE
syndrome were also enrolled through evaluation of medical
records. Photographs were reviewed when the individual with
CHARGE syndrome was not available for clinical assessment.
The research protocol was reviewed and approved by the Bay-
lor College of Medicine Institutional Review Board.
DNA Sequencing
Primers were designed using the program Primer 3, on the
basis of the annotated genomic sequence across each exon,
including regions of at least 40–50 bp of ﬂanking intervening
sequence (table A1). Larger exons were subdivided to allow
for optimal product lengths. All PCR reactions were performed
in a 25-ml reaction volume containing 40 ng of genomic DNA,
10 pmol of each primer, and 12.5 ml of Qiagen Multiplex PCR
Master Mix. Conditions for PCR were 15 min of initial ac-
tivation step at 95C, followed by 40 cycles of denaturation
at 94C for 30 s and annealing at 60C for 90 s, and a ﬁnal
extension at 72C for 60 s. An annealing temperature of 55C
was used for PCR ampliﬁcation of exons 30 and 38b. Se-
quencing of the CHD7 coding region (exons 2–38) for mu-
tations was performed using Big Dye Terminator Cycle Se-
quencing Reactions on an ABI 3700 (PE Applied Biosystems)
by use of the manufacturer’s standard protocol and reagents.
Sequence electropherograms were compared with gene se-
quences from GenBank accession number NM_017780. Se-
quence analysis of both the sense and antisense strands of the
PCR-ampliﬁed fragments was performed with the aid of Se-
quencher 4.5 software.
FISH
FISH was performed on DNA from 23 individuals with
CHARGE syndrome whose sequence analysis of CHD7 was
normal, by use of two clones, RP11-33I11 (GenBank accession
number AC113143) and RP11-174G1 (GenBank accession
number AC022182 ), encompassing theCHD7 gene. The BAC
clones were obtained from the Children’s Hospital Oakland
Research Institute BACPAC Resources Center. FISH analysis
was performed as described elsewhere (Lalani et al. 2003).
After hybridization and washing, biotinylated probes were de-
tected by avidin-ﬂuorescein, and digoxigenin-labeled probes
were detected using anti-digoxigenin antibody coupled with
rhodamine. The chromosome preparations were counter
stained with 4′,6-diamidino-2-phenylindole and were analyzed
with a Zeiss Axioskop ﬂuorescence microscope.
Mouse Embryo In Situ Hybridization
Whole-mount mouse embryo in situ hybridization was per-
formed at 10.5 d post coitum (dpc), with modiﬁcation of the
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Figure 3 Genomic and protein map of CHD7, indicating the spectrum of mutations in CHARGE syndrome. On the proteinmap, blackened
circles signify nonsense mutations, blackened diamonds signify frameshift mutations, unblackened squares signify missense mutations, and the
unblackened circle speciﬁes a mutation with an in-frame deletion of 3 aa. On the genomic sequence, triangles represent splice-site mutations.
protocol described elsewhere (Wilkinson 1992) and with the
use of blocking reagent (Boehringer Mannheim). Probes were
labeled using a DIG RNA Labeling kit (Boehringer Mann-
heim). Chd7 riboprobes were prepared from a cDNA frag-
ment (1587–2034) of KIAA1416 (GenBank accession number
BC034239). The probe spanning 447 bp in the 3′ region of
the gene was generated using PCR. The primers used for PCR
were forward primer 5′-GGAAACGACAATGAAGACGAG-
AAC-3′ and reverse primer 5′-CGTTTCCGGTGTTTTCTAT-
CTCAT-3′. In situ hybridization on sagittal sections of 10.5-
dpc embryos was performed using the same probe.
Microarray Analysis of Gene Expression
RNA was isolated from the lymphoblastoid cell lines of
seven mutation-positive, three mutation-negative, and ﬁve con-
trol samples by use of the Qiagen RNeasyMini kit. The quality
and purity of total RNA was assayed in a 2% agarose gel,
and the recovery was calculated after absorbance was mea-
sured with a spectrophotometer at 260 nm. Samples were la-
beled using the standard Affymetrix T7 oligo(dT) primer pro-
tocol and reagents supplied in the AffymetrixOne-CycleTarget
Labeling and Hybridization kit (catalog number 900493). To-
tal RNA was reverse transcribed to produce double-stranded
cDNA. The cDNA product was used as a template for the in
vitro transcription reaction, producing biotin-labeled cRNA.
The labeled cRNA was quantiﬁed by spectrophotometry
(NanoDrop ND-1000). Fifteen mg of the labeled cRNA was
fragmented and rechecked for concentration. A hybridization
cocktail containing Affymetrix spike-in controls and frag-
mented labeled cRNA was loaded onto GeneChip U133 2.0
Plus arrays. The array was hybridized overnight, for 16 h at
45C with rotation at 60 rpm. Arrays were then washed and
stained on Affymetrix Fluidics Station 400 equipment with a
strepavidin, R-phycoerythrin conjugate stain. Signal ampliﬁ-
cation was done using biotinylated anti-streptavidin. The
stained array was scanned on the Affymetrix GeneChip Scan-
ner 3000. The images were analyzed, and quality-control met-
rics were recorded using Affymetrix GCOS software, version
1.1.2. By use of reference standards, data were normalized
from different experiments and were compared with multiple
experiments on a quantitative level. The expression proﬁles of
both groups were compared and further evaluated with control
samples.
Affymetrix Data Analysis
Microarray data were analyzed with ChipST2C 1.14 (see
ChipST2C Web site). Normalization of the probe-level hy-
bridization data was performed using the Robust Multiarray
Average measure (Affy, R-package) (Irizarry et al. 2003a,
2003b). Pairwise T tests were used to compare expression val-
ues from individuals with CHARGE syndrome and CHD7
mutations ( ) with those from matched controls ( )np 7 np 5
by use of ChipST2C. With a threshold of , 116 tran-P ! .001
scripts were identiﬁed. The analysis was repeated for these
transcripts but with the addition of the individuals with
CHARGE syndrome without detectable CHD7 mutation
( ), by use of an F test (analysis of variance) and within-np 3
gene permutation to evaluate the empirical P values (Bp
iterations). Storey q values were calculated to estimate1,000
the positive false-discovery rate (Storey and Tibshirani 2003).
This resulted in 85 transcripts, with for all transcriptsq ! 0.01
(positive false-discovery rate 1%). The results are displayed
after hierarchical cluster analysis for genes (ﬁg. 2).
Phenotypic Data Analysis
Association of CHD7 mutations with clinical phenotypes
was computed using SPSS 12.0 (SPSS). The analysis was per-
formed for each clinical variable, and the analysis was com-
pared between mutation-positive and mutation-negative in-
dividuals. Types of mutations—including nonsense, frameshift,
missense, and splice-site mutations—and the position of the
mutations within the protein were analyzed and compared
with the phenotypic data of the individuals with CHARGE
syndrome. The Fisher’s exact test with 1 df was used for all
comparisons. The signiﬁcance threshold was set at . AllP ! .05
P values were two sided.
Results
Mutation Analysis
Among 110 individuals with clinical CHARGE syn-
drome in the study group, there were 105 sporadic cases;
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Table 1
CHD7 Mutations Observed in 64 Individuals with CHARGE
Syndrome
Mutation
Number Exon Individuala Mutation Originb Domain
1 2 95 Q112X NA
2 2 330 W145X De novo
3 2 3 Q180X De novo
4 2 315 T262fsX304 De novo
5 2 125 V424fsX466 NA
6 2 107 P366fsX377 De novo
7 2 134 R494X De novo
8 2 284 H556fsX564 De novo
9 3 28 G623fsX626 De novo
10 4 308 c.20971GrA De novo
11 4 297 c.22381GrA De novo
12 8 34 Q839fsX843 De novo Chromo
13 11 22 c.283615CrG NA
14 12 116 L1007C NA SNF2
15 12 71 T1027_P1029del De novo SNF2
16 12 233 W1031G De novo SNF2
17 13 66 R1069X De novo SNF2
18 13 281 R1069X De novo SNF2
19 13 119 V1070fsX1071 NA SNF2
20 14 307 E1152X NA
21 15 206 Q1214R De novo
22 15 158 c.37781GrA NA
23 16 172 E1271X NA
24 16 182 E1271X NA
25 16 215 L1294P De novo HELICc
26 17 151 R1339X De novo HELICc
27 17 184 R1339X De novo HELICc
28 18 236 V1409fsX1420 De novo
29 18 248 M1442fsX1443 De novo
30 19 221 R1465X NA
31 19 55 R1493fsX1501 De novo
32 20 146 W1534X De novo
33 20 171 L1545X De novo
34 21 9 R1571fsX1572 De novo
35 21 25 S1577X De novo
36 21 113 c.48501GrA De novo
37 22 58 c.50503ArT De novo
38 24 49 E1751fsX1752 NA
39 26 16 R1810X De novo
40 26 85 R1810X De novo
41 26 98 L1815P De novo
42 26 154 G1835fsX1843 De novo
43 26 143 c.55341GrT De novo
44 29 300 A1896fsX1898 NA
45 29 42 W1903X De novo
46 29 290 R1945X NA
47 30 287 C2017X De novo
48 30 29 R2024X De novo
49 30 339 c.61038CrT De novo
50 31 258 R2053X De novo
51 31 292 H2096R De novo
52 31 92 E2202fsX2208 De novo
53 33 166 R2319S Inherited
54 33 76 W2332X De novo
55 33 176 W2332X De novo
56 33 179 P2333fsX2334 De novo
57 34 239 E2450GfsX2468 De novo
58 34 203 K2510X De novo
59 35 224 c.783011ArG De novo
60 36 131 R2653X NA BRK
61 36 255 R2653X NA BRK
62 36 304 R2653X De novo BRK
63 37 37 Q2691fsX2709 NA
64 38 77 L2916fsX2940 NA
a For individual IDs, add “CHA” before the number shown.
b NA p not available.
four familial cases and one pair of MZ twins were also
included in the study. The individuals with CHARGE
syndrome comprised 61 (55%) females and 49 (45%)
males. Apparently pathogenic mutations in CHD7 were
found in 64 (58%) of the individuals with CHARGE
syndrome, distributed throughout the gene (ﬁg. 3 and
table 1). Truncating mutations were seen in 47 (73%)
of patients, including 28 stop-codon mutations and 19
frameshift mutations. Seven (11%) were missense mu-
tations, and 9 (14%) were intron-exon boundary mu-
tations (table 2). Either one or both parental samples
were unavailable for 17 (26%) of the mutation-positive
patients. All truncating mutations for which parental
samples were available were found to be de novo. Of
the seven missense mutations, parental samples were un-
available for one, ﬁve were found to be de novo, and
one was inherited from an affected mother. Of the nine
intron-exon boundary mutations, seven were found to
be de novo; parental samples were unavailable for the
other two. Three familial cases in this study group were
found to have mutations in the CHD7 gene (ﬁg. 4).
The missense mutation R2319S, seen in CHA166, was
also identiﬁed in the mother, who was mildly affected.
In another familial case, the E1271X mutation was
identiﬁed in both MZ twins. The nonsense mutation
W2332X was identiﬁed in a mildly affected girl whose
brother died of complications of CHARGE syndrome in
infancy. Althoughmost mutations were unique, R1339X
in exon 17, involving the HELICc domain, was present
in both CHA151 and CHA184; R1810X in exon 26
was observed in both CHA16 and CHA85; W2332X in
exon 33 was present in both CHA76 and CHA176; and
R2653X in exon 36, involving the BRK domain, was
present in three individuals: CHA131, CHA255, and
CHA304. One mutation was detected in the chromo-
domain, six in the SNF2 domain, three in the HELICc
domain, and three in the BRK domain.
Of 64 individuals with the CHD7 mutation, there
were 40 (63%) females and 24 (37%) males. No sex
difference was noted when they were compared with the
group without CHD7 mutations. Three of the clinical
criteria showed statistically signiﬁcant positive correla-
tions with the CHD7 mutation: cardiovascular malfor-
mations (54 of 59 in the mutation-positive group vs. 30
of 42 in the mutation-negative group; ), col-Pp .014
oboma of the iris, retinal, or optic nerve (55 of 62 in
the mutation-positive group vs. 30 of 43 in themutation-
negative group; ), and facial asymmetry (36 ofPp .022
56 in the mutation-positive group vs. 13 of 39 in the
mutation-negative group; ). There were no sig-Pp .004
niﬁcant differences between the two groups with respect
to choanal atresia, external or inner ear malformations,
deafness, cleft lip and palate, tracheoesophageal ﬁstula,
esophageal atresia, and urogenital abnormalities (table
3). The major and minor clinical diagnostic criteria
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Table 2
Summary of Mutations Observed in the CHD7 Gene in Individuals
with CHARGE Syndrome
Type of Mutation
Frequency
(n) De novo Inherited
Parental
Samples
Unavailable
Nonsense 28 20 0 8
Frameshift 19 13 0 6
In-frame deletion (3 aa) 1 1 0 0
Missense 7 5 1 1
Splice site 9 7 0 2
Figure 4 Five pedigrees with CHARGE syndrome illustrating
four familial cases and an affected pair of MZ twins.CHD7mutations
were identiﬁed in pedigrees CHA76, CHA166, and CHA172. Germ-
line mosaicism is suggested in CHA76, whereas CHA166 indicates
autosomal dominant transmission of the missense mutation in this
mildly affected family. CHA172 shows a nonsense mutation in MZ
twins. Mutations in CHD7 were not identiﬁed in families CHA192
and CHA88. Probands are indicated by arrows.
scores for each individual, as suggested by the criteria
from Blake et al. (1998) and Verloes (2005), were also
compared with mutation status. All 10 individuals with
the combined three major signs of Verloes (colobo-
ma, atresia of choanae, and hypoplastic semicircular ca-
nals) were found to have mutations in the CHD7 gene
( ).Pp .005
The phenotype-genotype analysis of the CHD7 mu-
tation-positive group revealed no clear correlation be-
tween the severity of the clinical ﬁndings and the type
of mutation. Individuals with a milder phenotype were
found to have mutations involving both the middle third
and the C-terminal part of the protein. Ten SNPs with
minor-allele frequency 10.01 in the white subjects
( ) were detected within the CHD7 gene (tablenp 86
4). There were no signiﬁcant differences in allele fre-
quencies between mutation carriers and noncarriers.
Mouse Embryo In Situ Hybridization
Previous research has shown that CHD7 expression
is widespread in human tissues, but the method used
did not allow estimation of relative expression levels
or correlation of expression pattern with the defects in
organogenesis observed in individuals with CHARGE.
Therefore, we examined the expression of the mouse
homolog, Chd7, at a stage in which the relevant anlage
might be visualized. Mouse embryo whole-mount and
section in situ hybridization at 10.5 dpc showed ex-
pression of Chd7 in the cardiac outﬂow tract, truncus
arteriosus, facio-acoustic (VII–VIII) preganglion com-
plex, hindbrain, forebrain, mandibular component of
the ﬁrst branchial arch, otic vesicle, optic stalk/optic ves-
icle, and olfactory pit (ﬁg. 5) (Kaufman 1992). Although
Chd7 is widely expressed, these tissues in the early em-
bryo exhibit differentially increased expression. The tis-
sues with high levels of expression appear to correspond
to the mature structures that are most severely affected
in CHARGE syndrome.
Gene-Expression Analysis
Because CHD7 is broadly expressed and because its
protein motifs suggest that it may play a role in global
regulation of chromatin structure, and hence gene ex-
pression, we wished to determine whether a character-
istic pattern of expression abnormality is associatedwith
mutation. Microarray analysis of gene-expression pat-
terns by use of lymphoblastoid cell lines from seven
CHD7 mutation-positive individuals showed signiﬁcant
gene expression differences when compared with those
from ﬁve control individuals and three affected individ-
uals with no detected mutation of CHD7 (ﬁg. 2). The
gene-expression signature created by the 116 transcripts
with the best statistical support shows that the cases and
controls cluster into two distinct groups. Interestingly,
individual CHA230 appears to cluster with the case pa-
tients bearing a CHD7 mutation, although we have not
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Table 3
Distribution of CHARGE Syndrome Features in CHD7 Mutation-Positive
and Mutation-Negative Individuals
SYNDROME FEATURE
NO. OF INDIVIDUALS WITH
FEATURE/NO. EVALUATED (%)
Pa
With
CHD7 Mutation
Without
CHD7 Mutation
Cardiovascular malformation 54/59 (92%) 30/42 (71%) .014
Coloboma 55/62 (89%) 30/43 (70%) .022
Facial asymmetry 36/56 (64%) 13/39 (33%) .004
Choanal atresia 34/57 (60%) 23/39 (59%) 1.000
Hearing loss 54/59 (92%) 36/38 (95%) .701
Inner ear abnormality 21/22 (95%) 9/10 (90%) .490
External ear malformation 59/62 (95%) 39/42 (93%) .683
Urogenital abnormality 29/53 (55%) 26/39 (67%) .287
Cleft lip/palate 18/60 (30%) 9/41 (22%) .493
Tracheoesophageal ﬁstula 10/55 (18%) 3/40 (8%) .226
a All P values are two sided. Signiﬁcant P values are in bold italics.
Table 4
Common CHD7 Polymorphisms
EXON POLYMORPHISM
FREQUENCY
Allele 1 Allele 2
2 c.166534GrA .793 .207
4 c.223839GrA .802 .198
6 c.244238ArT .976 .024
6 c.244293ArG .810 .190
9 c.261445GrA .779 .221
10 c.269854ArG .540 .460
15 c.352339CrG .989 .011
19 c.453345GrA .731 .269
31 c.6276GrA .971 .029
34 c.7356ArG .951 .049
been able to ﬁnd an alteration of the coding sequence
in that individual.
Discussion
CHARGE syndrome is a recognizable multiple-malfor-
mation syndrome, the etiology of which was unknown
until recently (Vissers et al. 2004). Autosomal domi-
nant inheritance in rare families (Mitchell et al. 1985),
concordance in MZ twins (Blake et al. 1989), advanced
paternal age (Tellier et al. 1996), and variable chromo-
somal abnormalities in rare individuals with CHARGE
syndrome (Clementi et al. 1991; Lee et al. 1995; North
et al. 1995; Devriendt et al. 1998; De Krijger et al. 1999;
Lev et al. 2000) supported a genetic basis for the con-
dition. Genomewide deletion screening by use of com-
parative genomic hybridization (CGH) (Sanlaville et al.
2002), STR markers (Lalani et al. 2003), and SNPs (La-
lani et al. 2005) in affected families did not identify
a common microdeletion in this syndrome. Vissers et
al. (2004) identiﬁed mutations in the gene for a chro-
modomain helicase DNA-binding protein, CHD7, in
10 of 17 individuals with CHARGE syndrome, after
BAC CGH analysis of two unrelated individuals with
CHARGE syndrome, one with an apparently balanced
translocation involving chromosomes 6 and 8. These
two subjects had overlapping microdeletions in chro-
mosome 8q12, both of which spanned the CHD7 locus.
Subsequent mutation analysis demonstrated that de
novo point mutations in this gene are associated with
CHARGE syndrome. Chromatin remodeling is an im-
portant mechanism for regulation of gene expression.
Like the other CHD genes, CHD7 is likely to play a
signiﬁcant role in development and cell-cycle regulation.
The gene encodes a protein with chromatin remodeling,
an SNF2-like ATPase/helicase domain, and DNA-bind-
ing motifs. CHD7 is 188 kb in length and is composed
of 38 exons, of which 37 are coding. In our study, path-
ogenic mutations were identiﬁed throughout the gene,
although many mutations were identiﬁed in exons that
encode the middle third of the protein. Most of the mu-
tations are truncating mutations that are likely to result
in haploinsufﬁciency. Most of the affected individuals
have de novo mutations in the CHD7 gene. However,
rare familial cases with recurrence were observed. In at
least one family in our study cohort, autosomal domi-
nant inheritance from the mother was documented. In
CHA166, the R2319S mutation seen in the proband was
also found in the affected mother who had iris colo-
boma, facial palsy, hearing loss, and delayed puberty.
Neither the mother nor the child had a cardiovascular
malformation. CHA76, a mildly affected girl, was found
to have truncating mutation W2332X, not present in
either of her parents. Interestingly, this child had a sibling
who died at age 6 mo due to complications related to
the diagnosis of CHARGE syndrome. The phenotype of
the deceased infant included coloboma, choanal atresia,
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Figure 5 Mouse embryo whole-mount and section in situ hy-
bridization showing the expression of Chd7. A, Whole-mount in situ
hybridization of the embryo at 10.5 dpc, demonstrating expression of
Chd7 in the craniofacial region. B, Expression of Chd7 observed in
cardiac outﬂow tract (OFT). LA p left atrium; RA p right atrium.
C, Sagittal section of embryo at 10.5 dpc, showing expression in the
facio-acoustic (VII–VIII) preganglion complex (FA), hindbrain (HB),
forebrain (FB), mandibular component of the ﬁrst branchial arch (BA),
and otic vesicle (OV). D and F, Sagittal section of embryo with ex-
pression in optic stalk/optic vesicle (OPV) and olfactory pit (OP). E
and G, Magniﬁed images of panel C, indicating expression of Chd7
in facio-acoustic preganglion complex and otic vesicle, with hematox-
ylin and eosin stain. H, Sagittal section of the embryo, demonstrating
expression in truncus arteriosus (TA) at 10.5 dpc.
hearing loss, pulmonary atresia with aortic stenosis and
ventricular septal defect, kidney abnormality, duodenal
atresia, and swallowing difﬁculties that necessitated G-
tube and Nissen fundoplication. A tissue sample was not
available for analysis from this sibling. Nonpaternity
was excluded for this study subject. These ﬁndings sug-
gest germline mosaicism in this family.
Proband CHA151 was found to have a de novo het-
erozygous mutation, R1339X, in the CHD7 gene. His
features included coloboma, choanal atresia, deafness,
ear malformation, undescended testes, and partial atrio-
ventricular canal. His sister was born with coarctation
of the aorta, and their mother had unilateral deafness
and mild facial palsy. The parents and sister were neg-
ative for the CHD7 R1339X mutation detected in the
proband. We conclude that, in this apparently familial
case, the clinical features in other family members are
unrelated to the R1339X mutation seen in the proband.
This study group also included a pair of female MZ
twins. Both had the nonsense mutation E1271X in ex-
on 16. They were born prematurely at 31 wk gestation.
Twin A died at age 4 mo due to sepsis, and a complete
autopsy was performed. The phenotype included bilat-
eral optic-nerve coloboma, complete atrioventricular ca-
nal defect, mild-to-moderate hypoplasia of the ascending
aorta, anomalous aortic arch branches including com-
mon brachiocephalic trunk, unilateral choanal atresia,
olfactory bulb hypoplasia, growth retardation, unilat-
eral cleft lip and palate, bilateral simpliﬁed ears, and
renal glomerular cysts. Twin B survived and had bilateral
coloboma, choanal stenosis, external ear malformation,
profound bilateral hearing loss, bilateral cleft lip and
palate, ventricular septal defect and patent ductus ar-
teriosus, growth retardation, and normal renal sono-
gram (table 5). The causes of phenotypic variation be-
tween MZ twins remain poorly understood. However,
the variation of phenotype in these twins could be ex-
plained by differential epigenetic regulation, such as var-
iable methylation, resulting in altered gene expression
and cellular phenotypes.
Cardiovascular malformations were more common in
the CHD7 mutation-positive group than in the muta-
tion-negative group. On the basis of its function in nu-
cleosome remodeling and transcription regulation, this
chromodomain helicase DNA-binding protein may af-
fect the functions of multiple genes involved in the pat-
terning of the cardiogenic developmental ﬁelds. Mouse
in situ hybridization studies demonstrate expression of
Chd7 in embryonic heart at 10.5 dpc. Assorted cardio-
vascular malformations are seen in the individuals with
CHARGE syndrome with CHD7 mutations, including
tetralogy of Fallot, septal defects, patent ductus arter-
iosus, coarctation of the aorta, and complete and partial
atrioventricular canal. Patent ductus arteriosus is more
common in the CHD7 mutation-positive group than
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Table 5
Clinical Features of CHARGE Syndrome in Familial Cases
CLINICAL FEATURES
CHA76 CHA166 CHA172 CHA192 CHA88
II1 II2 I2 II2 II1 II2 I1 II2 II3 II1 II2
Coloboma           
Choanal atresia           
Cranial nerve anomalies           
Hearing loss     U      
Inner ear abnormality U U U U U U U   U U
External ear malformation           
Cardiovascular malformation           
Urogenital abnormality           
Cleft lip/palate           
Tracheoesophageal ﬁstula           
Growth retardation           
Developmental delay       U    
NOTE.—U p unknown;  p presence;  p absence.
Table 6
Characterization of Verloes’s Major Signs in 32 Individuals
with CHARGE Syndrome
INDIVIDUALS
NO. OF VERLOES’S
MAJOR SIGNSa
TOTAL P1 2 3
CHD7 mutation negative 4 5 0 9
CHD7 mutation positive 1 12 10 23 .005
All 5 17 10 32
NOTE.—Signiﬁcant results are in bold italics.
a Major signs include coloboma (iris or choroid, with or without
microphthalmia), atresia of choanae, and hypoplastic semicircular ca-
nals (Verloes 2005).
in the mutation-negative group (31 of 54 vs. 7 of 38;
). There was no clear difference between theP ! .001
two groups with respect to other cardiovascular mal-
formations, including septal defects, left ventricular out-
ﬂow-tract obstructive lesions, tetralogy of Fallot, and
other outﬂow-tract anomalies. All ﬁve individuals with
CHARGE syndrome with atrioventricular canal defects
had CHD7 mutation; however, the number of individ-
uals with CHARGE syndrome with this cardiovascular
malformation was too small for meaningful comparison.
Postnatal growth retardation is known to be a distinct
phenotype in CHARGE syndrome. Various studies in-
dicate presence of growth retardation in ∼75% of in-
dividuals with CHARGE syndrome (Tellier et al. 1998).
The etiology of short stature in these individuals is not
understood in detail. Some children are known to have
growth-hormone deﬁciency, although systematic studies
of endocrine problems in these children are lacking.
In our study, growth retardation was obvious in both
CHD7 mutation carriers and noncarriers; however, the
Z scores of stature (normalized for age and sex) were
slightly lower for the mutation-positive group (mean
) than for the mutation-negative groupZp 2.5329
(mean ). Detailed endocrine evaluationZp 1.7594
of these individuals with CHARGE syndrome may iden-
tify speciﬁc endocrine defects caused by aberration of
CHD7 function.
Cranial nerve dysfunction, including facial and au-
ditory/vestibular nerves, is a major characteristic of
CHARGE syndrome. In our study, facial asymmetry was
observed more often in the CHD7 mutation-positive
group than in the mutation-negative group (36 of 56 vs.
13 of 39; ) (ﬁg. 1). Neuronal migration in ver-Pp .004
tebrate brain development is an important phenomenon,
and the migration of embryonic facial motoneurones in
mice and chicks has been studied extensively (Studer
2001). Despite detailed analyses, the cellular and mo-
lecular mechanisms that direct the migration of distinc-
tive neuronal populations remain largely unknown.
CHD7 may play a role in neuronal migration, either
directly or through its interaction with various partners,
thus causing the multiple cranial nerve dysfunction com-
monly observed in CHARGE syndrome.
We have detected CHD7 mutations in ∼60% of in-
dividuals with clinical CHARGE syndrome. Because
CHARGE syndrome has considerable phenotypic het-
erogeneity, clinical criteria were developed to aid reliable
diagnosis. Although individuals with four major criteria
or with three major and three minor criteria were des-
ignated as having deﬁnite CHARGE syndrome, the clin-
ical guidelines called for consideration of the diagnosis
of CHARGE syndrome in children with either one or
two major characteristics and multiple minor charac-
teristics (Blake et al. 1998). In our study, we included
these individuals given a possible diagnosis of CHARGE
syndrome and found pathogenic mutations in three of
them. Inner ear defects, including semicircular canal hy-
poplasia with or without Mondini malformation, is a
distinct feature of CHARGE syndrome. In our study
cohort, temporal bone CT scans were available for re-
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Table 7
Characterization of Blake’s Major Criteria in 98 Individuals
with CHARGE Syndrome
INDIVIDUALS
NO. OF BLAKE’S
MAJOR CRITERIAa
TOTAL P1 2 3 4
CHD7 mutation negative 1 10 16 12 39
CHD7 mutation positive 0 3 29 27 59 .014
All 1 13 45 39 98
a Major criteria include ocular coloboma (iris, retina, choroid, or
disc; microphthalmia), choanal atresia (unilateral/bilateral; stenosis/
atresia), cranial nerve anomalies (facial palsy-unilateral/bilateral, sen-
sorineural deafness, and/or swallowing problems), and characteristic
ear anomalies (external ear-lop or cup-shaped ear, middle ear ossicu-
lar malformations, mixed deafness, and cochlear defects) (Blake et al.
1998).
view for 32 individuals with CHARGE syndrome. Of
these, 30 (94%) had abnormal ﬁndings, with hypoplas-
tic or absent semicircular canals with or without Mon-
dini malformation. There was no statistically signiﬁcant
difference in the carriers and noncarriers of CHD7 mu-
tation when this clinical entity was separately analyzed
(8 of 9 in the mutation-negative group vs. 22 of 23
in the mutation-positive group; ). However,Pp .490
within this group of 32 individuals, for which temporal
bone imaging scans were available, Verloes’s major
signs—that is, iris or choroid coloboma, atresia of cho-
anae, and hypoplastic semicircular canals—were ana-
lyzed. Of the 32 individuals, 10 displayed all three of
Verloes’s major signs, and all were found to have a
CHD7 mutation ( ) (table 6). Interestingly, thesePp .005
10 individuals also displayed Blake’s four major criteria
and had associated cranial nerve dysfunction and char-
acteristic ear abnormalities. Eight of these individuals
also had a cardiovascular malformation.We suggest that
individuals with combined coloboma, choanal atresia,
and hypoplastic semicircular canals are likely to have
mutations in the CHD7 gene. Many individuals with all
four of Blake’s major criteria also have mutations in
CHD7 (table 7). The minor criteria of Verloes were dif-
ﬁcult to score accurately for each individual, because
growth hormone and gonadotropin deﬁciencies were not
documented for most of the individuals in the study
group. Also, formal assessment of mental retardation,
another minor sign, was not performed for these indi-
viduals. Similarly, distinctive CHARGE facies, one of
Blake’s minor criteria, was difﬁcult to score for many
individuals enrolled through the Baylor College of Med-
icine Cardiovascular Genetics Web site by various re-
ferring physicians.
In the initial study, CHD7 mutations and/or dele-
tions were seen in ∼63% (12/19) of individuals with
CHARGE syndrome (Vissers et al. 2004). These data
are similar to those of our present study and suggest that
CHARGE syndrome is likely a genetically heterogeneous
condition. This is also implied by various chromosomal
aberrations described in rare individuals with CHARGE.
Additionally, the microarray analysis of gene expression
with the use of lymphoblastoid cell lines from CHD7
mutation-positive and mutation-negative individuals
with CHARGE syndrome shows signiﬁcant gene ex-
pression differences between these two groups. The dif-
ferential gene-expression pattern in theCHD7mutation-
negative group may further assist in the understanding
of the molecular basis of the disorder in this group of
affected children. Previously, we reported a de novo mu-
tation in SEMA3E, a gene encoding a semaphorin pro-
tein involved in axon guidance and cell migration, in an
individual with CHARGE syndrome (CHA6). SEMA3E
became a candidate gene after a chromosomal break-
point was narrowed in an unrelated affected individual,
CHA193, with an apparently balanced chromosomal
translocation, 46,XY(2;7)(p14;q21.11), within 200 kb
of SEMA3E on chromosome 7 (Lalani et al. 2004). Both
CHA6 and CHA193 were studied for mutations in
CHD7. No mutation in the coding region or the exon-
intron boundaries of CHD7 was detected in these in-
dividuals. Moreover, the lymphoblast cell line from
CHA193 was also analyzed for gene-expression pattern
and was consistent with a signature pattern seen in
CHD7 mutation-negative individuals with CHARGE
(ﬁg. 2). It will be important to study the association
between CHD7 and this semaphorin protein gene in a
mutant animal model, to help further delineate the path-
ogenesis, particularly as it relates to the cranial nerve
dysfunction seen so frequently in individuals withCHD7
mutation.
No signiﬁcant distinct phenotype-genotype correla-
tions were identiﬁed for different types of CHD7 mu-
tations (missense, splice site, and truncating) in the mu-
tation-positive cohort. Similarly, no correlation was
observed between the clinical severity and the inferred
length of the mutant CHD7 protein. Three unrelated
individuals with CHARGE syndrome with the same mu-
tation, R2653X, in the BRK domain of the CHD7 gene
have different clinical phenotypes. We have also ob-
served variable expression of a CHD7 mutation within
individuals in the same family. The MZ twins with the
same mutation, E1271X, have differences in their phe-
notype; twin A had atrioventricular canal defect, and
twin B had a ventricular septal defect and patent ductus
arteriosus. CHA166, with the R2319S mutation, has iris
coloboma, ear malformation, mixed hearing loss, and
facial palsy. Her mother, who has the same mutation,
has iris coloboma, hearing loss, facial palsy, and a history
of delayed puberty.
There was no correlation of severity of phenotypewith
mutation in speciﬁc domains of the protein. However,
we have observed that ﬁve individuals with CHARGE
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syndrome with mutations in the SNF2 domain have var-
iable cardiovascular malformations.
In this study, the CHD7 mutations in the coding re-
gion and exon-intron boundaries were analyzed, and
these data were used for the statistical analyses. One
limitation of the study is the lack of sequence infor-
mation in the regulatory and promoter elements of the
CHD7 gene. Heterozygous deletions within the CHD7
gene may not have been detected by sequencing. We
addressed this concern by performing FISH analyses on
23 CHD7 mutation-negative individuals with CHARGE
syndrome, using RP11-33I11 and RP11-174G clones en-
compassing CHD7, and excluded any larger heterozy-
gous deletion in these individuals. However, microde-
letions of 100 kb could potentially be undetected by
the FISH methodology used.
Previously, the expression proﬁle by semiquantitative
RT-PCR analysis of CHD7 showed ubiquitous expres-
sion (Vissers et al. 2004). Mouse embryo in situ hy-
bridization, however, shows patterned expression of
Chd7 in tissues that are frequently affected in CHARGE
syndrome, such as optic stalk/optic vesicle, facio-acous-
tic preganglion complex, olfactory pit, forebrain, hind-
brain, mandibular component of the ﬁrst branchial arch,
and outﬂow tract of the heart. Remodeling of eukary-
otic chromatin is known to play a signiﬁcant role in
regulation of gene transcription. Tong et al. (1998) have
shown that the ATP-dependent nucleosome-remodeling
activity of the human histone deacetylase complex
derives from the helicase/ATPase domains of CHD3
(Mi-2a) and CHD4 (Mi-2b) proteins. This functionally
coupled complex is referred to as the “nucleosome re-
modeling and deacetylating (NuRD) complex.” The
NuRD complex from HeLa cells contains seven major
polypeptides, including Mi2, MTA2, MBD3, and the
histone deacetylase core, HDAC1/2 and RbAp46/48.
Current models suggest that NuRD complexes are in-
volved in producing a repressing chromatin environment
(Feng and Zhang 2001; Brehm et al. 2004). Through its
interaction with MBD3, a protein related to the methyl-
cytosine–binding protein, NuRD is involved in remod-
eling and deacetylating nucleosomes containing meth-
ylated DNA. It is also known that MeCP1 complex,
which is composed of 10 major polypeptides, including
MBD2, CHD3, and CHD4, and all of the other known
NuRD components, preferentially binds, remodels, and
deacetylates methylated nucleosomes to cause gene si-
lencing (Zhang et al. 1999). Another chromatin-remod-
eling protein, Chd1, is known to be a component of
yeast SAGA and SILK, two highly homologous and con-
served multisubunit histone acetyltransferase complexes
(Pray-Grant et al. 2005). Chd1 was shown to speciﬁcally
interact with the methylated lysine 4 mark on histone
H3, which is associated with transcriptional activity. The
association of CHD7 with histone deacetylases has not
been studied yet. It will be important to study the role
of this chromodomain helicase DNA-binding protein in
gene transcription and to understand its possible role in
gene repression.
In conclusion, CHD7 mutations account for ∼60%
of cases of CHARGE syndrome in our study. Cardio-
vascular malformations, coloboma, and facial asym-
metry were seen more often in those with mutations in
the CHD7 gene. We also suggest that most individuals
with CHARGE syndrome with combined coloboma,
choanal atresia, and hypoplastic semicircular canals will
have mutations in the CHD7 gene. Functional studies
are needed to address the question of how CHD7 mu-
tation alters gene expression, as expected on the basis
of its similarity to other chromodomain helicase DNA-
binding proteins.
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Appendix A
Table A1
CHD7 Oligonucleotide Sequences
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table A2
Annotated Transcript List from Microarray Cluster
Analysis
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Web Resources
Accession numbers and URLs for data presented herein are as
follows:
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Baylor College of Medicine Cardiovascular Genetics, http://www
.cardiogene.org/
ChipST2C, http://chipst2c.org/ChipST2C.html
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for gene sequences
[accessionnumberNM_017780], clonesRP11-33I11[accessionnumber
AC113143] and RP11-174G1 [accession number AC022182], and
cDNA fragment of KIAA1416 [accession number BC034239])
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm
.nih.gov/Omim/ (for CHARGE syndrome)
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